PLX.AMEXProtalix Biotherapeutics, INC
10-Q: Protalix BioTherapeutics Reports Q1 2025 Financial Results, Revenue Surges 170%
Sentiment:
Quarterly Report
Protalix BioTherapeutics reports a significant revenue increase of 170% in Q1 2025, driven by higher sales of Elelyso and progress in its clinical pipeline.
Capital raiseThe company sold 1,325,179 shares of common stock under the Sales Agreement, generating gross proceeds of approximately $3.0 million.In March 2025, the company amended the program to provide for the offer and sale of up to an additional $20.0 million.As of March 31, 2025, shares of Common Stock for total gross proceeds of approximately $19.7 million remain available to be sold under the Sales Agreement.
Better than expectedRevenue increased significantly by 170% compared to the same period last year.Net loss decreased compared to the same period last year.
Summary
- Protalix BioTherapeutics, Inc. reported its financial results for the quarter ended March 31, 2025.
- Total revenue increased significantly to $10.113 million, compared to $3.748 million in the same period last year.
- The increase in revenue was primarily driven by higher sales of goods, which reached $9.995 million compared to $3.677 million in the prior year.
- The company experienced a net loss of $3.619 million, or $0.05 per share, compared to a net loss of $4.595 million, or $0.06 per share, in Q1 2024.
- Research and development expenses increased to $3.475 million from $2.887 million year-over-year.
- Selling, general, and administrative expenses decreased to $2.603 million from $3.115 million year-over-year.
- As of March 31, 2025, the company's cash and cash equivalents and short-term bank deposits totaled $34.7 million.
- The company believes its current cash resources are sufficient to meet its capital needs for at least the next 12 months.
- The company sold 1,325,179 shares of common stock under the Sales Agreement, generating gross proceeds of approximately $3.0 million.
- Protalix is advancing its product pipeline, including PRX-115 for uncontrolled gout, with a Phase II clinical trial expected to commence in the second half of 2025.
Sentiment
Score: 7
Explanation: The document presents a positive outlook with significant revenue growth and a reduced net loss. However, ongoing risks and the need for potential future capital raises temper the overall sentiment.
Positives
- Significant revenue growth of 170% year-over-year indicates strong commercial performance.
- Decrease in net loss suggests improved operational efficiency.
- Healthy cash position of $34.7 million provides financial stability for ongoing operations and development programs.
- Advancement of PRX-115 into Phase II clinical trials represents progress in the company's pipeline.
- The company believes its current cash resources are sufficient to meet its capital needs for at least the next 12 months.
Negatives
- The company continues to experience net losses, although the loss has decreased compared to the previous year.
- Research and development expenses increased, reflecting higher investment in clinical trials, which may impact near-term profitability.
Risks
- The ongoing war in Israel could disrupt the company's operations, although the impact has not been adverse to date.
- The company's ability to raise additional capital depends on various factors, including the success of clinical trials and regulatory approvals.
- The company is dependent on performance by third-party providers of services and supplies, including clinical trial services.
- The company is dependent on its collaborators, distributors or partners, including, but not limited to, Pfizer Inc., or Pfizer, and Chiesi Farmaceutici S.p.A., or Chiesi.
Future Outlook
The company expects to continue incurring significant expenditures in research and development. They believe their current cash and cash equivalents are sufficient to satisfy capital needs for at least 12 months. A Phase II clinical trial of PRX-115 is expected to commence in the second half of 2025.
Industry Context
Protalix operates in the biopharmaceutical industry, focusing on rare and orphan diseases. The company competes with other players in the enzyme replacement therapy (ERT) market for Fabry and Gaucher diseases, including Sanofi, Takeda, and Amicus Therapeutics. The Fabry disease market is forecasted to grow at a CAGR of 6.6% from 2024-2030, reaching approximately $3.1 billion in annual sales in 2030.
Comparison to Industry Standards
- The global market for Gaucher disease, which includes Sanofi's Cerezyme, Shire's (acquired by Takeda Pharmaceutical Company Limited) Vpriv and Sanofi's Cerdelga, was $1.7 billion in 2024.
- The global market for Fabry disease, that includes agalsidase beta, Sanofi's Fabrazyme, agalsidase alfa, Shire's Replagal and Amicus Therapeutics Galafold, among others, is forecasted to be approximately $2.3 billion in 2025 and is forecasted to grow at a CAGR of 6.6% from 2024-2030 reaching approximately $3.1 billion in annual sales in 2030.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Bylaw Amendment | Amendment and restatement of Amended and Restated Bylaws to (i) provide that at any meeting of stockholders called for the purpose in the manner set forth in the Amended Bylaws, any director may be removed from office, with or without cause, by a majority of the stockholders entitled to vote at an election of directors; and (ii) remove the provision that prohibits stockholders from acting by written consent. | 2025-05-08 | The changes in the bylaws could make the company more vulnerable to activist investors. |
Stakeholder Impact
- Shareholders: Potential for increased value due to revenue growth and pipeline advancement.
- Employees: Continued employment and potential for growth within the company.
- Patients: Access to innovative therapies for rare diseases.
- Partners: Continued collaboration and potential for increased revenue.
Next Steps
- Commence Phase II clinical trial of PRX-115 in the second half of 2025.
- Continue commercialization efforts for Elfabrio and Elelyso.
- Continue to discuss with Fiocruz potential steps to maximize sales of BioManguinhos alfataliglicerase sales to the Brazilian MoH.
Key Dates
| Date | Description |
|---|---|
| 2012-05-XX | Elelyso was first approved by the FDA. |
| 2013-06-18 | The Company entered into a Supply and Technology Transfer Agreement (the Brazil Agreement) with Fiocruz for BioManguinhos alfataliglicerase. |
| 2014-08-XX | The FDA approved Elelyso for injection for pediatric patients. |
| 2015-10-XX | Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement. |
| 2017-10-19 | Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the Chiesi Ex-US Agreement). |
| 2018-07-23 | Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the Chiesi US Agreement). |
| 2023-02-27 | The Company entered into that certain At The Market Offering Agreement (as may be amended from time to time, the Sales Agreement) with H.C. Wainwright & Co., LLC, as the Company's sales agent (the Agent). |
| 2023-03-XX | The company initiated its phase I clinical trial of PRX-115 for the potential treatment of uncontrolled gout. |
| 2023-05-05 | The European Commission (EC) announced that it had approved the Marketing Authorization Application (MAA) for Elfabrio. |
| 2023-05-09 | The U.S. Food and Drug Administration (FDA) announced that it had approved the Biologics License Application (BLA) for Elfabrio (pegunigalsidase alfa). |
| 2024-09-XX | The Company repaid in full all of the outstanding principal and interest payable under its 7.50% Senior Secured Convertible Promissory Notes due 2024 (the 2024 Notes). |
| 2025-03-17 | The Company entered into an amendment to the Sales Agreement pursuant to which the Company increased the aggregate gross sales price of shares of Common Stock available for offer and sale under the Sales Agreement by $20.0 million. |
| 2025-03-31 | End of the reporting period for the financial results. |
| 2025-05-01 | Approximately 79,607,115 shares of the Registrants common stock, $0.001 par value, were outstanding. |
| 2025-05-08 | Our Board of Directors unanimously approved and adopted an amendment and restatement of our Amended and Restated Bylaws. |
| 2025-05-09 | Date of report filing. |
Keywords
Protalix, BioTherapeutics, Financial Results, Q1 2025, Revenue, Elfabrio, Elelyso, PRX-115, Gout, Fabry Disease, Gaucher Disease, Clinical Trials, Pharmaceuticals, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.